Skip to search formSkip to main contentSkip to account menu

GS-5885

Known as: GS 5885, GS5885, WHO 9796 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ledipasvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®
The advent of direct-acting antiviral agents (DAAs) has revolutionized the treatment and cure of chronic hepatitis C virus (HCV… 
2016
2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS 5 A Inhibitor Ledipasvir
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat… 
2014
2014
Trial of the Novel NS5A Inhibitor GS-5885 Resistance from a Multiple-Dose Clinical Characterization of Hepatitis C Virus
2013
2013
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… 
2013
2013
13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION
2012
2012
1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885
2011
2011
1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)